Dr. Reddy’s confirms Naloxone Hydrochloride Injection launch in the US
Category: #health  By Saipriya Iyer  Date: 2020-03-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Dr. Reddy’s confirms Naloxone Hydrochloride Injection launch in the US

Dr. Reddy’s Laboratories ,along with its subsidiaries, recently announced that the company has unveiled Naloxone Hydrochloride Injection USP, a prefilled Syringe of single-dose of 2mg/2mL which is a generic version of Narcan Injection USP, approved by the U.S. Food and Drug Administration.

Dr Reddy’s Laboratories’ Chief Executive Officer at North America Generics, Marc Kikuchi stated that the firm is looking forward to rolling out its second product in the market which has already been designated as a CGT (Competitive Generic Therapy) by the U.S. Food and Drug Administration.

Kikuchi further added that the company will have a 180-day of CGT exclusivity on account of the CGT designation to market the product.

According to reliable sources, the Naloxone Hydrochloride Injection USP, 2mg/2mL (1mg/mL) witnessed sales of $31 million MAT across the United States for all the past twelve months up till January 2020.

Apparently, the drug is mainly used to block any effects made by opioids. It is mostly used to reduce the breathing pattern when overdosed on opioid. Naloxone also has the ability to be used in combination with an opioid to lower the risks of misuse of the substances.

Citing sources familiar with the matter, the shares belonging to Dr. Reddy's Laboratories had been slogging down to 3.20% at Rs 2582.45 as the stock has crashed by 10.63% in four different sessions from the closing high of about Rs 2889.90, which had been recorded last on 13 March 2020.

For the record, Dr. Reddy's Laboratories is a pharmaceutical firm based in India. The company provides a vast portfolio of products as well as services with the help of its three different businesses covering global genetics, proprietary products, and pharmaceutical active ingredients and services.

The services provided by the company include custom pharmaceutical services (CPI), differentiated formulations, new chemical entities, generics, active pharmaceutical ingredients (API), and biosimilars.

Source Credit- https://www.business-standard.com/article/news-cm/dr-reddy-s-labs-launches-naloxone-hydrochloride-injection-in-us-120031900747_1.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba to acquire 10% stake in Yunda from controlling shareholders
Alibaba to acquire 10% stake in Yunda from controlling shareholders
By Saipriya Iyer

Alibaba Group Holding Limited, a Chinese multinational technology company, is reportedly planning to purchase nearly 10% stakes in Yunda Holding Co Ltd. This acquisition marks the e-Commerce company’s 5th investm...

Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
By Saipriya Iyer

A group of Amazon workers at its New York City facility reportedly held a walk out and went on strike over the lack of safety protocols by the e-Commerce giant, amid COVID-19 pandemic concerns. These workers further de...

Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
By Saipriya Iyer

Regeneron Pharmaceuticals, Inc. & Sanofi have recently announced the 1st patient to be treated in the COVID-19 clinical program, outside of the United States. The study, which is anticipated to enroll nearly 300 pa...